Primary splenic angiosarcoma is a rare and aggressive malignancy that should be considered in the differential diagnosis of patients presenting with thrombocytopenia and nonspecific symptoms.
Alerts clinicians to rare splenic tumors in unexplained thrombocytopenia; leaves open evidence-based surveillance protocols.
Primary splenic angiosarcoma is an extremely rare and aggressive vascular neoplasm associated with high rates of metastasis. A male patient in his 70s presented with thrombocytopenia. Physical examination and blood tests were non-revealing. A large splenic lesion was found on imaging, and splenectomy confirmed the diagnosis of splenic angiosarcoma. A PET scan and brain MRI showed no evidence of metastasis. The patient is now under surveillance with imaging. Primary splenic angiosarcoma presents a significant clinical challenge due to its aggressive nature and nonspecific symptoms, with outcomes typically poor despite treatment efforts. Chemotherapeutic options lack consensus due to the rarity of the disease. Most patients present with metastases, and treatment primarily involves resection, with adjuvant therapies considered based on risk factors. This case underscores the importance of considering rare malignancies in the differential diagnosis of patients presenting with thrombocytopenia and nonspecific symptoms. Early detection and prompt intervention are fundamental in improving outcomes.
No takes yet. Share an insight, caveat, or question.
Telvizian et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: